Corbus Pharmaceuticals Holdings, Inc. in 1 story
The narratives CRBP currently appears in, with its side and exposure in each.
Bull side
1 story- GLP-1 Eats Everything
CRBP in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Its oral peripheral CB1 inverse agonist monlunabant is a clinical-stage obesity candidate that could benefit from demand for convenient GLP-1 alternatives.
Bear side
0 storiesNo bear-side stories for CRBP yet.